Sugemalimab

DRUG5 trials

Sponsors

EQRx International, Inc., Sun Yat-sen University, CStone Pharmaceuticals, Sichuan University, Akeso

Conditions

Extensive-stage Small-cell Lung CancerExtranodal NK/T-cell LymphomaLimited Stage Small Cell Lung CancerLung CancerNSCLC (Non-small Cell Lung Cancer)

Phase 1

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

RecruitingNCT06217757

Sichuan UniversityExtensive-stage Small-cell Lung Cancer, Lung Cancer

Start: 2024-04-18End: 2027-03-20Target: 45Updated: 2024-05-13

Phase 2

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

RecruitingNCT05623267

Sun Yat-sen UniversityLimited Stage Small Cell Lung Cancer

Start: 2023-07-01End: 2027-03-31Target: 346Updated: 2023-08-07

Phase 3

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Not yet recruitingNCT05700448

CStone PharmaceuticalsExtranodal NK/T-cell Lymphoma

Start: 2026-06-01End: 2029-12-01Target: 150Updated: 2026-02-05

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

RecruitingNCT06617416

AkesoNSCLC (Non-small Cell Lung Cancer)

Start: 2024-11-12End: 2028-12-30Target: 560Updated: 2025-03-12

Unknown Phase

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

EQRx International, Inc.Extranodal NK/T-cell Lymphoma

Updated: 2023-03-27

Related Papers

Abstract 250: Targeting DNA damage repair pathway and CCR2+ myeloid cell to overcome radioimmunotherapy resistance in small cell lung cancer.

Cancer Research2026-04-03

Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.

2023-06-152 citations